3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

While three Wall Street analysts have bullish $100 price targets on Viking Therapeutics (implying a tripling), the author argues this is overly optimistic. Viking's weight-loss drug VK2735 would need near-flawless phase 3 data showing 23-26% mean weight loss to justify such gains, and any clinical setback could sink the stock. The author recommends only risk-tolerant investors consider a small position.